Boston Scientific's $3.7 Billion Acquisition of Axonics

Boston Scientific has agreed to acquire Axonics for approximately $3.7 billion, aiming to strengthen its urology business and expand into the high-growth sacral neuromodulation market. Axonics, based in California, develops neuromodulation systems for urinary and bowel dysfunction treatment. The acquisition is expected to be completed in the first half of 2024, with Boston Scientific projecting a highly accretive impact on its urology business in 2024. This move aligns with Boston Scientific's strategy of pursuing M&A to reinforce category leadership and enter faster growth markets.